Dediabetes Logo
Questions
Published answers connected to evidence
Clinical Reference
Detailed intervention and outcome dossiers
Latest Research
Newest studies
About
How deDiabetes works
Settings
Login / Sign-up
Research Summary
Analyzed using Evidence Intelligence™

Empagliflozin improves glycemic control in HNF1A-MODY

Powered by the Dediabetes Evidence Intelligence™ framework

Last updated July 12, 2026

Key finding

Empagliflozin lowered the mean glucose level 2.3 mmol/L (95% CI 1.3 to 3.3; P = 0.0001).

The study evaluated the effects of empagliflozin on glycemic control in adults with HNF1A-MODY, finding significant reductions in glucose levels and improvements in time in range.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Short-Term (≤3 mo)

Risk of bias

Some Concerns

Save research, organize studies, and quickly find important evidence again.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

The study evaluated the effects of empagliflozin on glycemic control in adults with HNF1A-MODY, finding significant reductions in glucose levels and improvements in time in range.

Clinical relevance

These findings are significant as they suggest that empagliflozin could be a valuable treatment option for adults with HNF1A-MODY, a rare form of diabetes. Improved glycemic control can lead to better long-term health outcomes, reducing the risk of diabetes-related complications. This study provides evidence that supports the use of empagliflozin in this specific population, potentially enhancing their quality of life.

Keep in mind

The study's sample size and generalizability may be limited due to the specific population. Potential unmeasured confounders could affect the outcomes. Effectiveness claims are based on statistical significance without assessing long-term clinical implications.

Published in

Journal Reference

Publication details and source links for this paper.

Henrik M, Stine OH, Johanne SJ, et al. Empagliflozin Improves Glycemic Control in Adults with HNF1A-MODY. Diabetes Care. 2026;49(7):1166-1174. doi:10.2337/dc25-2572

View DOIView on PubMedView on PMC

Main Effects

Empagliflozin lowered mean glucose levels by 2.3 mmol/L (P = 0.0001).

Time in range increased by 26% with empagliflozin compared to placebo (P = 0.0001).

Fasting plasma glucose decreased by 2.1 mmol/L (P = 0.0005).

Body weight decreased by 0.7 kg (P = 0.0016).

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Empagliflozin and Body weight, Fasting Plasma Glucose (FPG), Hypoglycemia events, and 2 more.

This study contributes evidence to

Intervention

Empagliflozin

Outcome

Body weight

Evidence topic

CGM Time in Range

Primary intervention

Empagliflozin

Primary outcomes

  • Body weight
  • Fasting Plasma Glucose (FPG)
  • Hypoglycemia events

Evidence topics

CGM Time in RangeGlycemic ControlFasting Blood GlucoseWeight Loss

Primary intervention

Empagliflozin

Primary outcomes

Body weightFasting Plasma Glucose (FPG)Hypoglycemia events

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

5
Evidence pairs
5
Relationships
5
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 72

5

Related topics

5

Evidence pairs

1170

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 5 evidence relationships
  • Includes primary outcome data
  • Linked to 5 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Add related evidence to your Evidence Tracker

Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Primary evidence

Evidence relationship

SGLT2 Inhibitors and Body Weight

Related evidence

Evidence relationship

SGLT2 Inhibitors and Fasting Glucose

Save evidence

Evidence relationship

SGLT2 Inhibitors and CGM Time in Range

Save evidence

Core evidence

Study findings

The primary outcomes reported in this study.

Body weight

Empagliflozin → Body weight

Empagliflozin → Body weight

Evidence Intelligence™
EvidenceScore™
83
Strong
ImpactScore™
67
Slightly Positive
ConsistencyScore™
83
consistent
Supporting studies: Based on 6 studies
Add to Evidence Tracker

Fasting Plasma Glucose (FPG)

Empagliflozin → Fasting Plasma Glucose (FPG)

Empagliflozin → Fasting Plasma Glucose (FPG)

Evidence Intelligence™
EvidenceScore™
Strong
Score 79 · Based on 4 studies
ImpactScore™
75
Positive
ConsistencyScore™
75
consistent
Supporting studies: Based on 4 studies
Add to Evidence Tracker

Hypoglycemia events

Empagliflozin → Hypoglycemia events

Empagliflozin → Hypoglycemia events

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Pre-meal mean glucose

Empagliflozin → Pre-meal mean glucose

Empagliflozin → Pre-meal mean glucose

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Time in range

Empagliflozin → Time in range

Empagliflozin → Time in range

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

evidence suggest

Evidence Suggest

  • Empagliflozin reduced mean glucose levels by 2.3 mmol/L.
  • Time in range improved by 26% with empagliflozin.
  • Fasting plasma glucose decreased by 2.1 mmol/L.
who this applies

Who this applies to

  • Adults diagnosed with HNF1A-MODY.
  • Individuals seeking improved glycemic control.
keep in mind

Keep in Mind

  • Results may not be applicable to other forms of diabetes.
  • Long-term effects of empagliflozin in this population remain to be studied.
  • Further research is needed to confirm findings in larger, more diverse populations.
between the lines

Between the Lines

  • The study's sample size and generalizability may be limited due to the specific population.
  • Potential unmeasured confounders could affect the outcomes.
  • Effectiveness claims are based on statistical significance without assessing long-term clinical implications.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Powered by the Dediabetes Evidence Intelligence™ framework

This study contributes to evidence on SGLT2 Inhibitors and Body Weight, SGLT2 Inhibitors and Fasting Glucose.

Related evidence relationships

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Do SGLT2 Inhibitors affect body weight?

Strong Evidence

SGLT2 Inhibitors may affect body weight.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Body weight

    EvidenceScore™ Strong | EvidenceScore™ 82.9 | weak positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 10 supporting studies with consistent results and a positive effect signal.

10 supporting studies
View Full Evidence

Do SGLT2 Inhibitors improve fasting glucose?

Strong Evidence

SGLT2 Inhibitors may improve fasting glucose.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Fasting Plasma Glucose (FPG)

    EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 12 supporting studies with consistent results and a positive effect signal.

12 supporting studies
View Full Evidence

Do SGLT2 Inhibitors improve CGM Time in Range?

Strong Evidence

SGLT2 Inhibitors may improve CGM Time in Range.

ConsistencyScore™: Results are generally consistent across studies.

Ranked evidence signals

  1. 1

    Pre-meal mean glucose

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

  2. 2

    Time in range

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on 3 supporting studies with generally consistent results and a positive effect signal.

3 supporting studies
View Full Evidence

Do SGLT2 Inhibitors affect hypoglycemia?

Moderate Evidence

Current evidence does not show a clear effect of SGLT2 Inhibitors on hypoglycemia.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Hypoglycemia events

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.

Limitations

  • Only a small number of supporting studies are available.
2 supporting studies
View Full Evidence
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

CGM Time in Range Evidence HubGlycemic Control Evidence HubFasting Blood Glucose Evidence HubWeight Loss Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Empagliflozin and Pre-meal mean glucoseAll studies on Empagliflozin and Body weightAll studies on Empagliflozin and Fasting Plasma Glucose (FPG)All studies on Empagliflozin and Hypoglycemia events

Related research

Read related research summaries.

Combination therapy improves liver health in type 2 diabetesEmpagliflozin does not change sympathetic activity in type 2 diabetesEmpagliflozin improves heart function in type 2 diabetes patientsEmpagliflozin improves glycemic control in type 2 diabetes patientsEmpagliflozin may reduce kidney disease biomarkers but shows mixed effects on albumin in early diabetes

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.